Money Concepts Capital Corp Raises Holdings in NeurAxis, Inc. $NRXS

Money Concepts Capital Corp boosted its stake in shares of NeurAxis, Inc. (NASDAQ:NRXS) by 566.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 222,605 shares of the company’s stock after acquiring an additional 189,210 shares during the quarter. Money Concepts Capital Corp’s holdings in NeurAxis were worth $1,011,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, Citadel Advisors LLC boosted its holdings in NeurAxis by 39.6% during the 3rd quarter. Citadel Advisors LLC now owns 35,627 shares of the company’s stock valued at $110,000 after acquiring an additional 10,103 shares during the period. Institutional investors and hedge funds own 11.77% of the company’s stock.

NeurAxis Stock Performance

NASDAQ NRXS opened at $7.91 on Thursday. NeurAxis, Inc. has a fifty-two week low of $2.07 and a fifty-two week high of $9.33. The stock has a 50 day simple moving average of $7.22 and a two-hundred day simple moving average of $5.00. The stock has a market cap of $91.00 million, a P/E ratio of -4.30 and a beta of 1.50.

Analyst Ratings Changes

Separately, Craig Hallum increased their target price on NeurAxis from $8.00 to $13.00 and gave the company a “buy” rating in a report on Friday, March 20th. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $13.00.

About NeurAxis

NeurAxis (NASDAQ: NRXS) is a clinical-stage biotechnology company focused on the discovery and development of therapeutic candidates for diseases of the central nervous system. The company leverages a proprietary approach to deliver small molecules and biologics across the blood–brain barrier, aiming to address conditions ranging from acute neural injury to chronic neurodegenerative disorders.

NeurAxis advances its pipeline through a combination of in-house research, external collaborations with academic medical centers and contract research organizations, and strategic licensing agreements.